한글목차

칸디다증 치료제 세계 시장은 2030년까지 52억 달러에 달할 전망

2023년에 43억 달러로 추정되는 칸디다증 치료제 세계 시장은 분석 기간 2023-2030년에 CAGR 3.1%로 성장하고, 2030년에는 52억 달러에 이를 것으로 예측됩니다. 이 보고서에서 분석한 부문 중 하나인 아졸 약제 클래스별은 CAGR 3.1%로 성장을 지속하고, 분석 기간 종료 시에는 27억 달러에 달할 것으로 예측됩니다. Equinocandin 의약품 등급별 부문의 성장률은 분석 기간 동안 CAGR 2.7%로 추정됩니다.

미국 시장은 11억 달러로 추정, 중국은 CAGR 3.0%로 성장 예측

미국 칸디다증 치료제 시장은 2023년 11억 달러로 추정됩니다. 세계 2위 경제대국인 중국은 2023-2030년간 CAGR 3.0%로 성장을 지속하여 2030년에는 8억 4,550만 달러 규모에 이를 것으로 예측되고 있습니다. 다른 주목할만한 지역별 시장으로는 일본과 캐나다가 있으며, 분석 기간 중 CAGR은 각각 2.9%와 2.5%로 예측되고 있습니다. 유럽에서는 독일이 CAGR 2.8%로 성장할 것으로 예측됩니다.

세계의 칸디다증 치료제 시장 - 주요 동향 및 촉진요인 요약

일반적으로 효모 감염으로 알려진 칸디다증은 칸디다 종에 의해 유발되는 곰팡이 감염이며 칸디다 알비칸스가 가장 흔합니다. 이러한 감염은 구강의 무성한 여드름과 질의 효모 감염과 같은 표면적, 특히 면역 결핍증과 같은 전신적이고 생명을 위협 할 수있는 상태까지 다양합니다. 칸디다증 치료제 시장에는 아졸계(플루코나졸 등), 에키노칸딘계, 폴리엔계(암포테리신 B 등) 등 다양한 항진균제가 포함되어 있습니다. 치료 상황은 효능을 높이고 부작용을 줄이는 새로운 제제와 약물 전달의 도입으로 해마다 크게 진화하고 있습니다. 또한, 진균 감염에 대한 의식 증가와 조기 진단의 중요성은 효과적인 칸디다증 치료제에 대한 수요에 박차를 가하고 있습니다.

칸디다증 치료제 시장은 성장 궤도를 형성하는 주목할만한 동향을 목격했습니다. 하나의 큰 추세는 약물 내성 칸디다 균주 증가이기 때문에 새로운 항진균제와 병용 요법의 개발이 필요합니다. 연구자들은 내성균을 이기기 위한 새로운 작용 메커니즘에 주목하고 있습니다. 게다가, 생명공학과 유전체학의 발전은 새로운 약물 표적의 확인과 보다 효과적인 치료법의 개발을 촉진하고 있습니다. 또한 개인의 유전자 프로파일과 곰팡이 감염의 특이한 특징을 바탕으로 치료 동향을 조정하는 맞춤형 의료에 대한 경향도 강해지고 있습니다. 또한 원격 의료 및 모바일 건강 앱과 같은 디지털 건강 기술의 통합은 환자의 치료에 대한 액세스와 복용 요법에 대한 충고를 향상시킵니다.

칸디다증 치료제 시장의 성장은 여러 요인에 의해 초래됩니다. 드래그 개발 및 약물전달 시스템의 기술적 진보로 보다 효율적이고 치밀한 치료가 가능해 시장이 확대되고 있습니다. 특히 고령화 사회와 HIV 환자나 화학요법을 받고 있는 암 환자 등 면역력이 저하되고 있는 사람들 사이에서 칸디다증의 유병률이 상승하고 있는 것이 큰 추진력이 되고 있습니다. 게다가 진균 감염에 대한 인식과 교육적 이니셔티브 증가는 조기 진단과 치료를 촉진하고 시장 수요를 끌어올리고 있습니다. 또한 소비자의 행동은 재발성 감염에 대한 의사의 조언과 시판 치료제를 추구하는 방향으로 이동하여 시장 성장에 기여하고 있습니다. 게다가 제약기업에 의한 연구개발에 대한 왕성한 투자와 항진균제의 신속한 승인을 위한 지원적인 규제 프레임워크은 항진균제 시장의 혁신과 확대를 촉진하고 있습니다.

조사 대상 기업 예(전 86건)

• AdvaCare Pharma
• Astellas Pharma Inc
• Atom Pharma
• Cadila Pharmaceuticals Ltd.
• F2G Ltd
• Gilead Sciences, Inc
• GlaxoSmithKline(GSK Plc)
• Matinas BioPharma Holdings, Inc
• Melinta Therapeutics, Inc.
• Merck & Co., Inc
• Pfizer Inc
• Pulmocide Ltd
• SCYNEXIS, Inc.
• Viatris
• Xellia Pharmaceuticals;

목차

제1장 조사 방법

제2장 주요 요약

• 시장 개요
• 주요 기업
• 시장 동향과 촉진요인
• 세계 시장 전망

제3장 시장 분석

• 미국
• 캐나다
• 일본
• 중국
• 유럽
• 프랑스
• 독일
• 이탈리아
• 영국
• 기타 유럽
• 아시아태평양
• 기타 지역

제4장 경쟁

영문목차

Global Candidiasis Drugs Market to Reach US$5.2 Billion by 2030

The global market for Candidiasis Drugs estimated at US$4.3 Billion in the year 2023, is expected to reach US$5.2 Billion by 2030, growing at a CAGR of 3.1% over the analysis period 2023-2030. Azoles Drug Class, one of the segments analyzed in the report, is expected to record a 3.1% CAGR and reach US$2.7 Billion by the end of the analysis period. Growth in the Echinocandins Drug Class segment is estimated at 2.7% CAGR over the analysis period.

The U.S. Market is Estimated at US$1.1 Billion While China is Forecast to Grow at 3.0% CAGR

The Candidiasis Drugs market in the U.S. is estimated at US$1.1 Billion in the year 2023. China, the world's second largest economy, is forecast to reach a projected market size of US$845.5 Million by the year 2030 trailing a CAGR of 3.0% over the analysis period 2023-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 2.9% and 2.5% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 2.8% CAGR.

Global Candidiasis Drugs Market - Key Trends and Drivers Summarized

Candidiasis, commonly known as yeast infection, is a fungal infection caused by Candida species, with Candida albicans being the most prevalent. These infections can range from superficial, such as oral thrush and vaginal yeast infections, to systemic and potentially life-threatening conditions, particularly in immunocompromised individuals. The candidiasis drugs market encompasses a variety of antifungal medications, including azoles (like fluconazole), echinocandins, and polyenes (such as amphotericin B). The treatment landscape has evolved significantly over the years with the introduction of new drug formulations and delivery methods that enhance efficacy and reduce side effects. Additionally, the growing awareness about fungal infections and the importance of early diagnosis have spurred the demand for effective candidiasis treatments.

The candidiasis drugs market has witnessed notable trends that are shaping its growth trajectory. One major trend is the increasing incidence of drug-resistant Candida strains, which has necessitated the development of new antifungal agents and combination therapies. Researchers are focusing on novel mechanisms of action to outpace the resistance. Additionally, advancements in biotechnology and genomics are facilitating the identification of new drug targets and the development of more effective treatments. There is also a growing trend towards personalized medicine, where treatments are tailored based on individual genetic profiles and specific characteristics of the fungal infection. Moreover, the integration of digital health technologies, such as telemedicine and mobile health apps, is improving patient access to treatment and adherence to medication regimens.

The growth in the candidiasis drugs market is driven by several factors. Technological advancements in drug development and delivery systems are enabling more efficient and targeted treatments, thus expanding the market. The rising prevalence of candidiasis, particularly among the aging population and those with weakened immune systems, such as HIV patients and cancer patients undergoing chemotherapy, is a significant driver. Additionally, increasing awareness and educational initiatives about fungal infections are prompting early diagnosis and treatment, thereby boosting market demand. Consumer behavior is also shifting towards seeking medical advice and over-the-counter treatments for recurrent infections, contributing to market growth. Furthermore, strong investment in research and development by pharmaceutical companies, along with supportive regulatory frameworks for fast-track approvals of antifungal drugs, is fostering innovation and expansion in the candidiasis drugs market.

Select Competitors (Total 86 Featured) -

• AdvaCare Pharma
• Astellas Pharma Inc
• Atom Pharma
• Cadila Pharmaceuticals Ltd.
• F2G Ltd
• Gilead Sciences, Inc
• GlaxoSmithKline (GSK Plc)
• Matinas BioPharma Holdings, Inc
• Melinta Therapeutics, Inc.
• Merck & Co., Inc
• Pfizer Inc
• Pulmocide Ltd
• SCYNEXIS, Inc.
• Viatris
• Xellia Pharmaceuticals;

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

• 1. MARKET OVERVIEW
  • Influencer Market Insights
  • Global Economic Update
  • Candidiasis Drugs - Global Key Competitors Percentage Market Share in 2024 (E)
  • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2024 (E)
• 2. FOCUS ON SELECT PLAYERS
• 3. MARKET TRENDS & DRIVERS
  • Innovative Antifungal Therapies Propel Growth in Candidiasis Drugs Market
  • Increasing Incidence of Drug-Resistant Strains Expands Addressable Market Opportunity
  • Advancements in Biotechnology and Genomics Strengthen Business Case for Novel Candidiasis Treatments
  • Rising Prevalence of Immunocompromised Conditions Spurs Demand for Effective Candidiasis Medications
  • Telemedicine and Mobile Health Apps Accelerate Demand for Convenient Candidiasis Medications
  • Growing Awareness and Early Diagnosis Throw the Spotlight on Candidiasis Drugs Market
  • Educational Initiatives Propel Growth by Promoting Early Detection and Treatment
  • Focus on Reducing Side Effects Enhances the Business Case for New Antifungal Medications
  • Evolving Drug Delivery Systems Generate Opportunities in the Candidiasis Drugs Market
  • Increasing Healthcare Expenditure Sustains Growth in Demand for Advanced Candidiasis Treatments
  • Innovations in Pharmacogenomics Strengthen Market Position of Personalized Candidiasis Drugs
  • Advancements in Combination Therapies Drive Adoption and Market Growth
  • Rise in Outpatient Treatment Models Propels Demand for Easily Accessible Candidiasis Medications
• 4. GLOBAL MARKET PERSPECTIVE
  • TABLE 1: World Candidiasis Drugs Market Analysis of Annual Sales in US$ Million for Years 2014 through 2030
  • TABLE 2: World Recent Past, Current & Future Analysis for Candidiasis Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
  • TABLE 3: World Historic Review for Candidiasis Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 4: World 16-Year Perspective for Candidiasis Drugs by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets for Years 2014, 2024 & 2030
  • TABLE 5: World Recent Past, Current & Future Analysis for Azoles by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
  • TABLE 6: World Historic Review for Azoles by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 7: World 16-Year Perspective for Azoles by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
  • TABLE 8: World Recent Past, Current & Future Analysis for Echinocandins by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
  • TABLE 9: World Historic Review for Echinocandins by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 10: World 16-Year Perspective for Echinocandins by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
  • TABLE 11: World Recent Past, Current & Future Analysis for Other Drugs Classes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
  • TABLE 12: World Historic Review for Other Drugs Classes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 13: World 16-Year Perspective for Other Drugs Classes by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030

III. MARKET ANALYSIS

• UNITED STATES
  • Candidiasis Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2024 (E)
  • TABLE 14: USA Recent Past, Current & Future Analysis for Candidiasis Drugs by Drug Class - Azoles, Echinocandins and Other Drugs Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 15: USA Historic Review for Candidiasis Drugs by Drug Class - Azoles, Echinocandins and Other Drugs Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 16: USA 16-Year Perspective for Candidiasis Drugs by Drug Class - Percentage Breakdown of Value Sales for Azoles, Echinocandins and Other Drugs Classes for the Years 2014, 2024 & 2030
• CANADA
  • TABLE 17: Canada Recent Past, Current & Future Analysis for Candidiasis Drugs by Drug Class - Azoles, Echinocandins and Other Drugs Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 18: Canada Historic Review for Candidiasis Drugs by Drug Class - Azoles, Echinocandins and Other Drugs Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 19: Canada 16-Year Perspective for Candidiasis Drugs by Drug Class - Percentage Breakdown of Value Sales for Azoles, Echinocandins and Other Drugs Classes for the Years 2014, 2024 & 2030
• JAPAN
  • Candidiasis Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2024 (E)
  • TABLE 20: Japan Recent Past, Current & Future Analysis for Candidiasis Drugs by Drug Class - Azoles, Echinocandins and Other Drugs Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 21: Japan Historic Review for Candidiasis Drugs by Drug Class - Azoles, Echinocandins and Other Drugs Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 22: Japan 16-Year Perspective for Candidiasis Drugs by Drug Class - Percentage Breakdown of Value Sales for Azoles, Echinocandins and Other Drugs Classes for the Years 2014, 2024 & 2030
• CHINA
  • Candidiasis Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2024 (E)
  • TABLE 23: China Recent Past, Current & Future Analysis for Candidiasis Drugs by Drug Class - Azoles, Echinocandins and Other Drugs Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 24: China Historic Review for Candidiasis Drugs by Drug Class - Azoles, Echinocandins and Other Drugs Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 25: China 16-Year Perspective for Candidiasis Drugs by Drug Class - Percentage Breakdown of Value Sales for Azoles, Echinocandins and Other Drugs Classes for the Years 2014, 2024 & 2030
• EUROPE
  • Candidiasis Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2024 (E)
  • TABLE 26: Europe Recent Past, Current & Future Analysis for Candidiasis Drugs by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
  • TABLE 27: Europe Historic Review for Candidiasis Drugs by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 28: Europe 16-Year Perspective for Candidiasis Drugs by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK and Rest of Europe Markets for Years 2014, 2024 & 2030
  • TABLE 29: Europe Recent Past, Current & Future Analysis for Candidiasis Drugs by Drug Class - Azoles, Echinocandins and Other Drugs Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 30: Europe Historic Review for Candidiasis Drugs by Drug Class - Azoles, Echinocandins and Other Drugs Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 31: Europe 16-Year Perspective for Candidiasis Drugs by Drug Class - Percentage Breakdown of Value Sales for Azoles, Echinocandins and Other Drugs Classes for the Years 2014, 2024 & 2030
• FRANCE
  • Candidiasis Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2024 (E)
  • TABLE 32: France Recent Past, Current & Future Analysis for Candidiasis Drugs by Drug Class - Azoles, Echinocandins and Other Drugs Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 33: France Historic Review for Candidiasis Drugs by Drug Class - Azoles, Echinocandins and Other Drugs Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 34: France 16-Year Perspective for Candidiasis Drugs by Drug Class - Percentage Breakdown of Value Sales for Azoles, Echinocandins and Other Drugs Classes for the Years 2014, 2024 & 2030
• GERMANY
  • Candidiasis Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2024 (E)
  • TABLE 35: Germany Recent Past, Current & Future Analysis for Candidiasis Drugs by Drug Class - Azoles, Echinocandins and Other Drugs Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 36: Germany Historic Review for Candidiasis Drugs by Drug Class - Azoles, Echinocandins and Other Drugs Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 37: Germany 16-Year Perspective for Candidiasis Drugs by Drug Class - Percentage Breakdown of Value Sales for Azoles, Echinocandins and Other Drugs Classes for the Years 2014, 2024 & 2030
• ITALY
  • TABLE 38: Italy Recent Past, Current & Future Analysis for Candidiasis Drugs by Drug Class - Azoles, Echinocandins and Other Drugs Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 39: Italy Historic Review for Candidiasis Drugs by Drug Class - Azoles, Echinocandins and Other Drugs Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 40: Italy 16-Year Perspective for Candidiasis Drugs by Drug Class - Percentage Breakdown of Value Sales for Azoles, Echinocandins and Other Drugs Classes for the Years 2014, 2024 & 2030
• UNITED KINGDOM
  • Candidiasis Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2024 (E)
  • TABLE 41: UK Recent Past, Current & Future Analysis for Candidiasis Drugs by Drug Class - Azoles, Echinocandins and Other Drugs Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 42: UK Historic Review for Candidiasis Drugs by Drug Class - Azoles, Echinocandins and Other Drugs Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 43: UK 16-Year Perspective for Candidiasis Drugs by Drug Class - Percentage Breakdown of Value Sales for Azoles, Echinocandins and Other Drugs Classes for the Years 2014, 2024 & 2030
• REST OF EUROPE
  • TABLE 44: Rest of Europe Recent Past, Current & Future Analysis for Candidiasis Drugs by Drug Class - Azoles, Echinocandins and Other Drugs Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 45: Rest of Europe Historic Review for Candidiasis Drugs by Drug Class - Azoles, Echinocandins and Other Drugs Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 46: Rest of Europe 16-Year Perspective for Candidiasis Drugs by Drug Class - Percentage Breakdown of Value Sales for Azoles, Echinocandins and Other Drugs Classes for the Years 2014, 2024 & 2030
• ASIA-PACIFIC
  • Candidiasis Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2024 (E)
  • TABLE 47: Asia-Pacific Recent Past, Current & Future Analysis for Candidiasis Drugs by Drug Class - Azoles, Echinocandins and Other Drugs Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 48: Asia-Pacific Historic Review for Candidiasis Drugs by Drug Class - Azoles, Echinocandins and Other Drugs Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 49: Asia-Pacific 16-Year Perspective for Candidiasis Drugs by Drug Class - Percentage Breakdown of Value Sales for Azoles, Echinocandins and Other Drugs Classes for the Years 2014, 2024 & 2030
• REST OF WORLD
  • TABLE 50: Rest of World Recent Past, Current & Future Analysis for Candidiasis Drugs by Drug Class - Azoles, Echinocandins and Other Drugs Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 51: Rest of World Historic Review for Candidiasis Drugs by Drug Class - Azoles, Echinocandins and Other Drugs Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 52: Rest of World 16-Year Perspective for Candidiasis Drugs by Drug Class - Percentage Breakdown of Value Sales for Azoles, Echinocandins and Other Drugs Classes for the Years 2014, 2024 & 2030

IV. COMPETITION